A Phase 2 Study of PEGylated Recombinant Human Growth Hormone for 52 Weeks in Short Children Born Small for Gestational Age in China.

Clin Endocrinol (Oxf) · 2025 · PMC11694553 · PMID 39513569

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

IGF‐1 SDS and IGF‐1/IGFBP‐3 Both the IGF‐1 SDS and the IGF‐1/IGFBP‐3 ratio showed an increasing trend, and a clear dose‐dependent response was observed with elevated levels at all evaluation points (Figure 2B,C ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.